The Immunogenomics and Systems Biology Core (ISCB) is a multidisciplinary program that provides data management, analytics and disease translation for the AMP AIM Network. The ISCB supports ongoing efforts of the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases Network (AMP AIM) to deepen our understanding of the cellular and molecular interactions that lead to inflammation and autoimmune diseases involving the skin.
Building on the U-M Department of Dermatology’s extensive experience in the development of genetics and systems biology approaches, the ISCB works with a broad range of multi-omics data including genetic, epigenetic, single-cell and spatial-seq data to increase our understanding of the factors that contribute to disease and heterogeneity. The ISCB utilizes advanced analytical approaches in causal mechanism inference, modeling and single cell and spatial genomics data integration. The integration of genetic information with other -omics data collected through the AMP AIM network will help to accelerate discovery of critical pathogenic mechanisms and to unravel the biologic processes contributing to disease heterogeneity.
The AMP AIM network is part of a long-standing collaboration among the National Institutes of Health, the U.S. Food and Drug Administration, pharmaceutical companies, and nonprofit organizations. AMP AIM investigators are focusing their research on rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriasis, psoriatic arthritis, and Sjögren’s disease. Knowledge gained through these studies will advance the development of new and enhanced treatments for autoimmune diseases, and will drive the development of new research tools, data storage platforms, and data sharing technologies.